Efficacy and Safety of HRS-7535 Tablets in T2DM Subjects Poorly Controlled With Metformin and SGLT2i.

Inclusion Criteria: 1. Male or female subjects, 18-75 years of age at the time of signing informed consent; 2. Have T2DM (based on the 2020 Chinese Diabetes Society \[CDS\] diagnostic criteria) 3. HbA1c为7.5%≤HbA1c≤11.0% at the screening visit； 4. FPG≤15 mmol/L at the screening visit; 5. Have been treated with an SGLT2i with metformin, for at least 8 weeks; 6. At screening and random visit, 20.0 ≤BMI≤ 35.0 kg/m2; 7. Able and willing to provide a written informed consent Exclusion Criteria: 1. Have type 1 diabetesmellitus; 2. History of acute cardiovascular and cerebrovascular diseases within 6 months prior to screening; 3. Any organ-system malignancies developed within 5 years except for cured local basal cell cancer of the skin and in-situ cancer of the cervix; 4. history of blood donation or blood loss in the 3 months before screening, or blood transfusion in the 2 months before screening; 5. Surgery is planned during the trial; 6. Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using an adequate contraceptive method;